ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Boston, MA, USA:

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

combined with IL-15 superagonist (N-803) in recurrent, high grade ovarian cancer (HGOC).Names of the study therapies involved in th...

Not yet enrolling
Ovarian Carcinoma, Recurrent
Recurrent Ovary Cancer
Biological: IL-15 Superagonist
Biological: Cytokine-Induced Memory-like Natural Killer Cells

Phase 1

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 1 other location

The goal of this clinical trial is to compare participants with ovarian, fallopian tube or primary peritoneal cancer when treated w...

Active, not recruiting
Ovarian Neoplasms
Ovarian Cancer
Biological: Vigil
Other: Placebo

Phase 2

Gradalis

Boston, Massachusetts, United States and 25 other locations

This study is testing whether a 6 week skills-based telehealth intervention can help ovarian cancer patients experiencing PARP inhi...

Active, not recruiting
Ovarian Cancer
Coping Skills
Behavioral: REVITALIZE ACT Intervention
Behavioral: Enhanced Usual Care (EOC)
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 1 other location

This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer...

Enrolling
Endometrial Cancer
Ovarian Cancer
Drug: Metformin
Drug: LY3023414

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 2 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Olaparib 300mg tablets
Drug: Placebo to match olaparib 300mg

Phase 3

AstraZeneca
AstraZeneca

Boston, Massachusetts, United States and 125 other locations

in combination with paclitaxel and carboplatin (AUC4) when compared with carboplatin (AUC6) and paclitaxel alone in patients with advanced ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Drug: carboplatin
Drug: carboplatin

Phase 2

AstraZeneca
AstraZeneca

Boston, Massachusetts, United States and 41 other locations

clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib in subjects with platinum-resistant ovarian...

Enrolling
Fallopian Tube Cancer
Ovarian Cancer
Drug: Niraparib
Drug: ZN-c3

Phase 1, Phase 2

K-Group Beta

Providence, Rhode Island, United States and 18 other locations

positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...

Active, not recruiting
Primary Peritoneal Cancer
High Grade Ovarian Cancer
Drug: Mirvetuximab soravtansine
Drug: Carboplatin

Phase 2

ImmunoGen
ImmunoGen

Boston, Massachusetts, United States and 70 other locations

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Alpelisib
Drug: Pegylated liposomal doxorubicin (PLD)

Phase 3

Novartis
Novartis

Boston, Massachusetts, United States and 93 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Boston, Massachusetts, United States and 176 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems